197 Serum interleukin-2 levels in the first 24–72 hours post CD19 CAR T cell infusion is a robust biomarker of CAR T cell expansion in leukemia and lymphoma patients treated with Axi-cel or Brexu-cel
Chad M. Williams, Davide Bedognetti(Sidra Medical and Research Center), Mike Mattie, Justin A. Budka(Gilead Sciences (United Kingdom)), Saran Vardhanabhuti, Wangshu Zhang
Cited by 0
Related Papers
The Immune Landscape of Cancer
|Immunity|2018|6.3k
The Immune Landscape of Cancer
|Immunity|2019|806
Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma
|New England Journal of Medicine|2023|437
Common variation in KITLG and at 5q31.3 predisposes to testicular germ cell cancer
|Nature Genetics|2009|353
Reduction of Immunosuppression as Initial Therapy for Posttransplantation Lymphoproliferative Disorder★
|American Journal of Transplantation|2011|218